Ambassadors

Bristi Basu

Cancer Research UK Consultant Medical Oncologist in Experimental Cancer Therapeutics at Cambridge University Hospitals NHS Trust, UK

Dr Bristi Basu is a Cancer Research UK Consultant Medical Oncologist in Experimental Cancer Therapeutics at Cambridge University Hospitals NHS Trust (UK). She trained in Medicine at Oxford University before undertaking clinical specialty training in Medical Oncology at Cambridge. During this time, she completed a PhD in cancer cell biology and drug discovery at the University of Cambridge. She has worked with experimental cancer therapy agents in several early phase trials both at Addenbrooke’s Hospital, Cambridge and at the Drug Development Unit, Royal Marsden Hospital, Surrey.

She hopes to improve outcomes for patients with pancreatic cancer by utilising her background to translate some of the exciting findings arising from pre-clinical research at Cambridge, when designing and running clinical studies of novel anticancer drugs.


Antonino Carbone

Chairman of the Department of Pathology, Centro di Riferimento, Oncologico Aviano, Istituto Nazionale Tumori, IRCCS, (Aviano, Italy)

Dr Carbone served as Chairman of the Department of Pathology and Laboratory Medicine of the Istituto Nazionale dei Tumori – Milano, Italy until 2009. He is the Chairman of the Division of Pathology of the CRO, Istituto Nazionale Tumori – Aviano, Italy. Dr Carbone is internationally recognized for his diagnostic expertise and for his many scholarly accomplishments in hematopathology. He is actively involved in the writing group of the WHO IARC Monograph Working Group on Biological Agents and Cancer, and is the Chairman of the Italian TNM Staging Committee of the UICC. He has published more than 700 scientific papers, primarily in hematopathology, in international peer-reviewed journals (h-index: 76).


Fatima Cardoso

ESO Breast Cancer Program Coordinator; EORTC Secretary General; Director, Breast Cancer Unit, Champalimaud Cancer Center Lisbon, Portugal

Dr Cardoso is the Director of the Breast Cancer Unit of the Champalimaud Cancer Center in Lisbon, Portugal. Dr Cardoso earned her medical degree at the University of Porto in Portugal and completed fellowships in the Translational Research Unit of the Jules Bordet Institute (IJB) in Brussels, Belgium (Prof. Martine Piccart), and the Department of Molecular and Cellular Oncology at MD Anderson Cancer Center in Houston, Texas (Prof. Mien-Chie Hung). She then worked for 10 years as Assistant Professor at the Medical Oncology Clinic of the IJB where, besides her clinical work, she was active in the Translational Research Unit and was responsible for Phase II–III trials in breast cancer. She is board certified in medical oncology and internal medicine.

Dr Cardoso’s research interests include biology of breast cancer, prognostic and predictive markers of response to systemic therapy, and new anticancer agents. She is actively involved in a number of Phase I–III breast cancer clinical trials and served as the scientific director of the international research network TRANSBIG for 7 years.

Dr Cardoso is actively involved in numerous professional organizations such as ESMO, ECCO, EORTC, ASCO, and AACR where she serves on several committees, including the ECCO Board of Directors and is the current EORTC Secretary General and vice-chair of the EORTC-Breast Cancer Group. She is the Breast Cancer Program Coordinator of the European School of Oncology and co-chair of the Advanced Breast Cancer International Consensus Guidelines Conference (ABC).

Dr Cardoso is editor-in-chief of The Breast Journal, associate editor of the European Journal of Cancer, and an editorial board member of several other journals.

She has received several educational and research grants from the Breast Cancer Research Foundation, the European Society of Medical Oncology (ESMO), the European Cancer Organization (ECCO), the Portuguese Science and Technology Foundation (FCT), the Portuguese League Against Cancer, the Portuguese Ministry of Health, the Free University of Brussels, the “Fonds Jean-Claude Heuson”, the Fondation Lambeau-Marteau, the Belgian Federation Against Cancer, the Susan G. Komen Foundation, and the European Union Framework VI Programme.

Dr Cardoso has authored over 200 publications and has presented her work nationally and internationally.


Chamberlain photoMarc Chamberlain

Professor of Neurology and Neurological Surgery. Chief, Division of Neuro-Oncology, University of Washington School of Medicine, Seattle, WA, USA

Professor of Neurology and Neurological Surgery, Chief, Division of Neuro-Oncology and an affiliated member of the Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA at the University of Washington School of Medicine. He received a BS (biochemistry) and BA (zoology) from the University of California, Berkeley in 1973 and his MD from Columbia University, College of Physicians and Surgeons in 1977. After completing a pediatric residency in 1980 and neurology residency in 1985 at the University of California, Los Angeles, CA, he became and completed a neuro-oncology fellowship at the University of California, San Francisco in 1986. He became the program leader of neuro-oncology at the University of California, San Diego (1986-1997), the University of Southern California, Los Angeles, CA (1997-2003), Moffitt Cancer Center, Tampa, FL (2003-2007) and the University of Washington, Seattle, WA (2007-present).

Dr. Chamberlain serves or has served on a number of advisory boards (Schering-Plough, Genentech/Roche, ENZON, Merck Serono, Lilly/Immclone, Pfizer, Merck,Sigma-Tau, Plexxicon, Mundipharma), speakers bureau’s (Schering-Plough, Genentech, Exilexis, Myriad, ENZON, Mundipharma), editorial boards (Neuro-Oncology, CNS Oncology, Cancer, CNS Drugs, Journal of Neuro-Oncology) and national professional organizations (Society of Neuro-Oncology, American Society of Clinical Oncologists, American Academy of Neurology, Radiation Treatment Oncology Group).

He has published over 300 papers in various peer-reviewed journals including Neurology, Cancer, Journal of Clinical Oncology, Lancet Oncology, Neurosurgery, Journal of Neurosurgery, Neuro-Oncology, Journal of Neuro-Oncology, CNS Oncology and Archives of Neurology and developed many of the methods used today in evaluating and managing neoplastic meningitis.


headshot ChotiMichael A. Choti

Chair of the Department of Surgery and Surgeon-in-Chief University of Texas Southwestern Medical Center (TX,USA)

Dr Choti received his MD degree at Yale University, general surgery training at the University of Pennsylvania, and completed the surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center before joining the division of Surgical Oncology at Johns Hopkins. In 2013, Dr Choti moved to University of Texas Southwestern Medical Center as the Hall and Mary Lucille Shannon Professor of Surgery and Chair of the Department of Surgery.

Dr Choti serves on various leadership positions in national and international societies and has chaired study sections for the American Cancer Society. He served as Chair of the NCI-CTEP Hepatobiliary Task Force and the Director of the NCCN Neuroendocrine Tumor database. He also served on the American College of Surgeons’ Commission on Cancer, the GI committees of NSABP and ACOSOG, and the Colorectal Cancer and Neuroendocrine Tumors Guidelines Panels of NCCN. Dr Choti is a member of the Surgical Oncology Board of the American Board of Surgery.

Dr Choti is the principal or co-investigator for a variety of clinical and preclinical studies examining new approaches for the treatment of liver, pancreatic, and colorectal cancer. In addition to clinical research, Dr Choti also maintains an active laboratory effort in the use of robotics and computer assistance to surgically treat gastrointestinal malignancies. This work has been funded through a series of NIH grants and industry collaborations. He also has a strong interest in molecular genetics and biomarkers in gastrointestinal cancer. He has more than 300 peer-reviewed publications.

Education and patient advocacy has also been important to Dr Choti. He serves on the medical advisory boards for several foundations related to GI cancer. He has directed educational symposia and served on program committees for ASCO, AHPBA, among others.


AnnickAnnick Desjardins

Associate Professor, Department of Neurology & Director of Clinical Research at the Preston Robert Tisch Brain Tumor Center at Duke Medical Center (NC, USA)

Annick Desjardins, MD, FRCPC., is Associate Professor within the Department of Neurology and is the Director of Clinical Research at the Preston Robert Tisch Brain Tumor Center at Duke University (NC, USA). In 2003, Dr Desjardins completed her residency in Adult Neurology at the Universite de Sherbrooke, Quebec, Canada. Following a 2-year fellowship in neuro-oncology at The Preston Robert Tisch Brain Tumor Center at Duke, she joined the Center as faculty, in July 2005.

Dr Desjardins is a Fellow of the Royal College of Physicians of Canada. She has been the Principal Investigator on over 30 therapeutic trials in neuro-oncology, including investigator initiated and international multicenter studies, and has held several INDs. She has over 75 peer-review publications and five book chapters.

Dr Desjardins has written invited expert reviews for Hospital Pharmacy Europe, Nature Review Neurology, Clinical Care Options and MEDscape CME. She is reviewer for Cancer, Journal of Neuro-Oncology, Expert Review of Anticancer Therapy, Cancer Research, Molecular Cancer Therapeutics and Future Oncology.


Edelman-DSC_0684Martin J. Edelman

Associate Director for Clinical Research at University of New Mexico Cancer Center, The Victor and Ruby Hansen Surface Endowed Chair in Clinical Research (NM,USA)

Dr Edelman is Professor of Hematology/Oncology, The Victor and Ruby Hansen Surface Endowed Chair in Clinical Research and Associate Director for Clinical Research at University of New Mexico Cancer Center (NM, USA).

After leaving active military service, Dr. Edelman joined the faculty at the University of California, Davis and the VA Northern California Health Care System in 1990. He later became Chief of the Division of Hematology and Oncology at the VA. He was a member of the VA National Technical Advisory Group for Oncology and chaired the VA National Oncology Conference for four years. While at UC Davis he was co-director of the thoracic oncology program and developed several trials in lung cancer. In addition, he also initiated trials in GU malignancies, developmental therapeutics and supportive care.

Dr. Edelman was a member of the Lung Cancer and GU committees of the Southwest Oncology Group (SWOG) and chaired two SWOG Phase II trials in lung cancer, both based upon pilot studies performed at UC Davis. In 1999, Dr. Edelman moved to the University of Maryland Greenebaum Cancer Center in Baltimore. He is the Director for Solid Tumor Oncology and clinical leader of the Experimental Therapeutics Program as well as the institutional Principal Investigator for the Cancer and Leukemia Group B (CALGB) at Maryland.

He is a member of the Respiratory Core Committee of the Alliance ( CALGB) and is medical oncology co-chair for the Lung Cancer Steering Committee for RTOG. Currently he leads trials in lung cancer in the Alliance (CALGB) and RTOG as well as a number of clinical and laboratory studies investigating new agents in cancer at the University of Maryland. Dr. Edelman has served as a member of the NIH subcommittee H, the ASCO program committee and several NIH study sections.

In addition, he is Associate Editor of the journal Lung Cancer. This summer he will be moving the University of New Mexico Cancer Center to become Associate Director for Clinical Research.


Escudier HeadshotBernard Escudier

Head of the French Group of Immunotherapy, Institute of Gustave Roussy, Paris, France

Dr Bernard Escudier trained in Paris. He received his MD in 1981 as a cardiologist, and moved to Gustave Roussy Institute in 1983, initially in the Intensive Care Unit, and then took the lead of the Immunotherapy Unit, mainly in charge of developing programs in renal cell carcinoma and in melanoma. His largest fields of interest are renal cell carcinoma, immunotherapy (cytokines, vaccines), and development of new strategies (antiangiogenic drugs, gene therapy). He has been largely involved in the development of new targeted therapies for RCC, and has been the PI of many trials in the field of RCC, from phase I to phase III.

Dr Escudier has been head of the French Group of Immunotherapy since 1992, and is the chairman of the GU tumor board at Gustave Roussy Institute in Villejuif, France. He is a member of ASCO, AACR, ESMO, and has been the chair of the GU Group of ESMO from 2008 to 2010, and is currently the ESMO faculty coordinator for the GU group. He has published more than 290 papers in peer reviewed journals, mainly in the field of Renal Cancer.


HeadshotSteven Eric Finkelstein

National Director, 21st Century Oncology Translational Research Consortium

Dr Finkelstein is a Board Certified Radiation Oncologist and National Director, 21st Century Oncology Translational Research Consortium (TRC); Adjunct Associate Professor, Translational Genomics Research Institute (TGEN); Director, TRC Animal Radiation-Imaging-Immunotherapy Experimental Laboratory (ARIEL); National Principal Investigator, Radiation Therapy Oncology Group (RTOG)-21C; and Executive Director, Arizona Cancer Research Alliance (ACRA)

Dr Finkelstein received his MD from the University of Michigan in 1997 graduating cum laude eruditionis causa. He joined the National Cancer Institute in 1999 and completed both Surgical Oncology and Clinical Immunotherapy Fellowship in 2004. Following completion of Chief Resident in Radiation Oncology at MCC, he joined the 21st Century Oncology Translational Research Consortium (TRC) and was appointed its Director in 2011. In that role, he is responsible for advancing patient access to novel, advanced cancer care.

Dr Finkelstein has published journal articles and book chapters resulting in 2000+ reference citations in the literature and gives national and international lectures on utilizing “cutting edge” radiation driven, personalized systemic therapy. He has received numerous prestigious awards across specialties, including but not limited to RSNA Roentgen Award, American College of Surgeons, First Place for Clinical, and iSBTc 18th Presidential Award.


Goel headshotAjay Goel

Director of Epigenetics and Cancer Prevention at Baylor Research Institute, Baylor University Medical Center, Dallas (TX, USA)

Ajay Goel is Director of Epigenetics and Cancer Prevention at Baylor Research Institute, Baylor University Medical Center in Dallas, TX. Dr Goel has spent 20 years researching cancer and has been the lead author or contributor to over 150 scientific articles published in peer reviewed international journals and several book chapters. He is also a primary inventor on more than 14 patents aimed at developing various biomarkers for the diagnosis, prognosis and prediction of gastrointestinal cancers. He is currently using advanced genomic and transcriptomic approaches to develop novel DNA- and microRNAbased biomarkers for the early detection of colorectal cancers. In addition, he is researching the prevention of gastrointestinal cancers using integrative and alternative approaches, including botanical products such as curcumin (from turmeric) and boswellia.

Dr Goel is a member of the American Association for Cancer Research (AACR) and the American Gastroenterology Association (AGA) and is on the international editorial boards of several journals including Gastroenterology, Clinical Cancer Research, PLoS ONE and World Journal of Gastroenterology. He is also actively involved in peer reviewing activities for more than 75 international scientific journals and various grant review panels of various national and international funding organizations. His research has been actively funded by various private and federal organizations, including funding from the National Institutes of Health (NIH) and American Cancer Society (ACS). His many awards include the Union of European Gastroenterology Federation’s Distinguished Researcher Award and multiple Posters of Distinction Awards from the AGA.


Frederic W. Grannis Jr

Clinical Professor of Thoracic Surgery at City of Hope National Medical Center (CA,USA)

Frederic W. Grannis Jr. M.D. is Clinical Professor of Thoracic Surgery at City of Hope National Medical Center. He has spent most of his adult life treating disease caused by tobacco products, including lung cancer, coronary, carotid and peripheral artery disease and chronic obstructive lung disease and emphysema. His extensive experience in the palliative care of patients in the end stages of lung cancer lead to his recognition that treatment of symptomatic, late-stage disease yields poor results and is enormously expensive. He has spent the past 30 years advocating a multi-pronged approach toward disease caused by tobacco products, including first, public policy directed toward prevention of initiation of smoking, particularly among young people, second, improved methods and systems to assist smokers to quit and third, to screen to detect disease in early stage where it can be managed with more effective, less-costly and less-debilitating treatments. He has testified in medical monitoring lawsuits in the states of Massachusetts, New York and California in the belief that tobacco companies should pay the costs of smoking cessation and screening programs for the benefit of their current and former customers.


Cary P. Gross

Associate Professor and Co-Director of the Robert Wood Johnson Clinical Scholars Program, Yale University (CT, USA)

Dr. Gross is an Associate Professor and the Co-Director of the Robert Wood Johnson Clinical Scholars Program at Yale. As Director of the Cancer Outcomes Public Policy and Effectiveness Research (COPPER) Center at Yale, the over-arching theme of his work is the disconnect between evidence generated from clinical research and the actual needs of older persons with cancer.

He uses comparative effectiveness studies and policy-relevant research to address this important knowledge gap. As a general internist, Dr. Gross has received NIH-funded grants to explore barriers to trial enrollment as well as the impact of non-cancer illnesses on older cancer patients.

Ongoing investigations focus on the understanding variability and value in cancer care, with a focus on incorporating patient centered outcomes.

Dr. Gross and his colleagues have used state-of-the-art techniques including hierarchical modeling and propensity score analysis to shed new insights about cancer screening, as well as the care and outcomes of older persons with cancer. The resulting findings have been published in high-impact journals including the Journal of the National Cancer Institute.


Nadia Harbeck

Head of Breast Center, Oncological Therapy and Breast Clinical Trials Unit, University of München, Germany

Nadia Harbeck, MD, PhD, is the head of the Breast Center, Oncological Therapy and Breast Clinical Trials Unit, and holds the chair for Conservative Oncology at the Department of Obstetrics & Gynecology (Hospitals Grosshadern and Maistrasse-Innenstadt), University of Munich (Ludwig-Maximilians-Universitӓt München [LMU]), Germany. From 2009-2011, she was head of the Breast Center at the University of Cologne, Germany. Until 2009, she was an Associate Professor and Head of Conservative Senology at the Technical University of Munich, where she started her specialist training in 1990 and also obtained her specialist degree (Obstetrics & Gynecology) in 1998. In 1989, she received her medical degree from the University of Munich (LMU).

Professor Harbeck is a member of the expert panel issuing the yearly updated evidence-based Working Group for Gynecologic Oncology (AGO) Guidelines for breast cancer therapy in Germany (www.ago-online.de). In addition, she is an executive board member of the European Organisation for Research and Treatment of Cancer (EORTC) and a steering committee member of the EORTC PathoBiology Group, as well as a member of numerous other professional organisations.

Professor Harbeck is Scientific Director of the West German Study Group (WSG, a BIG member), which focuses on early breast cancer trials with a strong translational research program. She is principal investigator or steering committee member of numerous national and international clinical breast cancer trials, with a recent focus on trials using novel targeted compounds. She is a member of the TransHERA committee, as well as co-chair of TransALTTO committee. Her translational research focuses on prognostic and predictive factors in breast cancer and other solid tumors.

Professor Harbeck has authored more than 280 papers in peer-reviewed journals (cumulative impact factor ~ 1200) and is coordinating editor-in-chief of Breast Care. For her clinical translational research, she has received numerous awards, including the 2012 Claudia von Schilling Award, the 2002 AGO Schmidt-Matthiesen Award, a 2001 American Association for Cancer Research (AACR) Research Award, and the 2001 American Society of Clinical Oncology (ASCO) Fellowship Merit Award for the highest ranking abstract submitted. Professor Harbeck was invited to give a keynote lecture at the Danish Cancer Society in 2010, the opening lecture at IBCM-2 2009, a keynote lecture at the 2008 Congress of the German Cancer Society (DKG), and the Emmanuel van der Schueren Lecture at the 2008 European Breast Cancer Conference (EBCC-6). In 2011, Professor Harbeck co-chaired the 3rd IMPAKT meeting and the EORTC-NCI-ASCO Meeting on Molecular Markers. She is also a faculty and panel member of the International Conference on Breast Cancer in Young Women (1st BCY 2012) and of the International Consensus on Advanced Breast Cancer (ABC 2011 & 2013).


KurzrockRazelle Kurzrock

Sr. Deputy Center Director, Clinical Science; Director, Center for Personalized Cancer Therapy; CTO, Vice Chief, Division of Hematology and Oncology, UC San Diego Moores Cancer Center (CA, USA)

Dr Razelle Kurzrock joined UC San Diego Moores Cancer Center in November 2012 as Senior Deputy Center Director for Clinical Science and Murray Professor of Meicine. Her role is broad, including growing and innovating the clinical trials program, and directing the Clinical Trials Office as well as the newly established Center for Personalized Therapy. She also serves as Vice Chief of the Division of Hematology Oncology for the UC San Diego School of Medicine, and is scheduled to assume the Chief position in July 2014. As a physician–scientist, Dr Kurzrock brings extraordinary expertise and experience in clinical research, business operations, regulatory operations, financial and budget planning, and administrative oversight, in addition to her world-recognized work in translational science.

Dr Kurzrock is best known for successfully creating the largest Phase I clinical trials department in the world while at the University of Texas M.D. Anderson Cancer Center. She was the Chair of this department designated Investigational Cancer Therapeutics from its inception until August 2012 when she moved to UC San Diego Moores Cancer Center. In FY12 alone, this department enrolled approximately 1,200 patients on 128 therapeutic trials. Dr Kurzrock’s unique approach emphasized using cutting-edge molecular profiling technologies to match patients with novel targeted therapies reflecting a personalized strategy to optimize cancer treatment.

Dr Kurzrock has served as the Principal Investigator (PI) on more than 90 clinical trials, and has overseen approximately 300 clinical trials, mainly using novel targeted molecules, several of which have gone on to FDA approval. She has been the Principal Investigator of the National Cancer Institute U01 Phase I Studies of Targeted Anti-Cancer Agents. She has also been the PI and co-PI of multiple other awards including the University of Texas Clinical and Translational Science Award (co-PI; 35 million dollars).

Dr Kurzrock also created and directed two innovative education programs: the MS/PhD program in Patient-Based Biological Research (U. of Texas Graduate School of Biomedical Sciences) as well as the Phase I Clinical Trials Fellowship. She has been awarded numerous grants and contracts totaling more than $10 million in FY12 alone, and has published nearly 500 peer-reviewed articles in a variety of elite medical journals. In addition, she is Chair of the Southwest Oncology Group (SWOG) Early Therapeutics Committee and on their Board of Governors. More recently, she also joined the Board of Directors for the National Comprehensive Cancer Network (NCCN).


Nick Lemoine

Director, Barts Cancer Institute at Barts and the London School of Medicine and Dentistry (London, UK)

Professor Nick Lemoine is the Director of the Institute of Cancer at Barts and the London School of Medicine and Dentistry, and leads the Barts Experimental Cancer Medicine Centre. Professor Lemoine is an international expert in pancreatic cancer and much of his work focuses on this disease.

As Lead for the Centre for Experimental Cancer Medicine, Professor Lemoine is responsible for the management of a 40-strong team who support over 120 clinical trials currently open at Barts.

Nick Lemoine was Professor of Molecular Pathology at Imperial College London (UK), where he was Director of the Cancer Research UK Molecular Oncology Unit and the first Director of the National Translational Cancer Research Centre at Hammersmith Hospital. Professor Lemoine trained in medicine at St Bartholomew’s Hospital Medical College where he qualified with the University of London Gold Medal in 1983, specialising in pathology and oncology with posts in London and Cardiff.

Professor Lemoine recently stepped down as Chairman of the MRC Clinical Research & Career Development Panel and the National Institute of Health Research Clinician Scientist Appointments & Review Panel. He previously chaired the MRC Stem Cell Fellowship Panel, the CR-UK Clinician Scientist and Senior Clinician Fellowship Panel and the MRC Experimental Medicine Review Panel for the Molecular & Cellular Medicine Board. Professor Lemoine has been a long-serving member of the Gene Therapy Advisory Committee at the Department of Health, as well as CR-UK Science Funding Committee, MRC Molecular & Cellular Medicine Board and CORE Scientific Advisory Board.

Professor Lemoine has been the Editor of the Nature Specialist Journal Gene Therapy since 1997, and his research into the molecular genetics of cancer and gene therapy is funded by programme grants from Cancer Research UK, Digestive Cancer Campaign and the European Union. Professor Lemoine was elected a fellow of the Academy of Medical Sciences in 2006.


Simon Lo

Associate Professor of Radiation Oncology, Case Western Reserve University School of Medicine (OH, USA)

Simon Lo is currently Associate Professor of Radiation Oncology at Case Western Reserve University and Director of Radiosurgery Services and Neurologic Radiation Oncology at UH Seidman Cancer Center. His clinical and research interests are brain, skull base and spinal tumors, lung cancer, liver cancer, stereotactic radiosurgery and stereotactic body radiotherapy. He is currently chair of the American College of Radiology Appropriateness Criteria Expert Panel in Bone Metastasis (non-spine and spine). Dr Lo has written more than 90 peer-reviewed manuscripts and more than 30 book chapters, and is editing a textbook on stereotactic body radiotherapy. He has lectured in numerous international and national meetings as well as numerous prestigious academic cancer centers.


Christos J. Markopoulos, MD, PhD, FEBS

Professor of Surgery, Medical School of the National and Kapodistrian University of Athens, Greece

Christos J. Markopoulos is Professor of Surgery at the Medical School of the National and Kapodistrian University of Athens, Greece. He is also the Director of both the Breast Unit at ‘Laiko’ University Hospital of Athens and Athens Medical Centre, Greece.

He graduated from Athens Medical School in 1979. Specialized in general surgery, he received his PhD degree from Athens University in 1985. He also holds an MPhil degree in Oncology–Breast Cancer from the University of London, UK (1988).

He specialized in breast cancer management while working as senior registrar in surgery at the Breast Unit of St George’s Hospital and Medical School and at The Royal Marsden Hospital in London (UK) (1985–1988). He has also worked as a research fellow at the Ludwing Institute for Cancer Research in Sutton, United Kingdom.

Professor Markopoulos has published over 350 scientific papers in international and Greek medical journals with over 3,000 citations and also authored several books on breast disease. He is an elected member of the Executive Committee of the European Society of Breast Cancer Specialists (EUSOMA) and he is Vice-President of the UEMS-European Board of Surgery – Division of Breast Surgery and examiner of the European Breast Surgery Qualification (EBSQ) exams. He is also member of several medical associations and societies including the British Association of Surgical Oncology (BASO), Association of Breast Surgery at The Royal College of Surgeons (ABS), American College of Breast Surgeons (ACBS), European Society of Surgical Oncology (ESSO). Since 2000, he has been chair of The Hellenic Society of Breast Surgeons (HSBS) and responsible for the education, training and clinical trials section of the Society. He has created the elective course on Breast Disease for the final year students of Athens Medical School. He is the national coordinator for various international trials, president or member of scientific committees of Greek breast cancer advocacy groups and Europa Donna Hellas. Professor Markopoulos has organized a large number of national and international postgraduate courses and meetings on breast cancer over the last 30 years and has lectured extensively as an invited speaker in national and international congresses.


munsterPamela N. Munster

Program Leader, Developmental Therapeutics & Director, Early Phase Clinical Trials, Division of Hematology/Oncology, University of California, San Francisco (USA)

Dr Munster received her medical degree from the University of Bern, Switzerland; completed her residency in Internal Medicine at Indiana University Medical Center then moved to Memorial Sloan-Kettering Cancer Center, New York for her oncology and hematology fellowship. She continued at Memorial Sloan Kettering as a faculty member in the breast cancer program before joining the Division of Breast Oncology and Experimental Therapeutics Program at H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

Dr Munster served as the Scientific Director of Breast Research and Co-Chair of the Phase I Program at Moffitt for six years prior to moving to San Francisco. Currently Dr Munster is Professor in Residence at the University of California, San Francisco and the Director of Early Phase Clinical Trials Program at the Helen Diller Family Comprehensive Cancer Center.

Her basic laboratory research interests are in the area of developing novel targeted therapy for the treatment of breast cancer and their integration into current treatment strategies. Dr Munster’s research interest involves basic research studies on epigenetic modification of DNA repair and therapy resistance. Her laboratory is involved in several projects testing HDAC inhibitors reverse hormone therapy resistance in breast cancer and to potentiate chemotherapy by inhibiting DNA repair. Dr Munster’s clinical research interests are in the area of early anti-tumor drug development with focus on drugs that target the epidermal growth factor family members and the topoisomerase family members. In addition to her interest in drug development, Dr Munster has a special interest in the preservation of fertility in young patients undergoing cancer therapy.

Dr Munster has published in several scientific journals and has given lectures on topics such as the management of metastatic breast cancer, breast cancer receptors, clinical trials and translational research.


Pawlik HeadshotTimothy M. Pawlik

Director, Johns Hopkins Medicine Liver Tumor Center Multi-Disciplinary Clinic; Professor of Surgery and Oncology, Chief, Division of Surgical Oncology, John L. Cameron M.D. Professor of Alimentary Tract Diseases, Johns Hopkins Hospital (MD, USA)

Dr Pawlik received his undergraduate degree from Georgetown University and his medical degree from Tufts University School of Medicine. Dr Pawlik completed surgical training at the University of Michigan Hospital and spent two years at the Massachusetts General Hospital as a surgical oncology research fellow. He then went on for advanced training in surgical oncology at The University of Texas M. D. Anderson Cancer Center in Houston. Dr Pawlik’s main clinical interests include alimentary tract surgery, with a special interest in hepatic and pancreatobiliary diseases. Dr. Pawlik also has an interest in medical ethics and completed a fellowship in medical ethics at the Harvard School of Public Health as well as a Masters in Theology from Harvard Divinity School in Boston. In addition, Dr Pawlik has received a PhD from the Johns Hopkins Bloomberg School of Public Health in Clinical Investigations.

Dr Pawlik took his first faculty appointment at Johns Hopkins in 2005, where he is currently Professor of Surgery and Oncology, as well as the Director of the Johns Hopkins Liver Tumor Clinic. Dr Pawlik holds the John L. Cameron Chair of Alimentary Tract Diseases and is Chief of the Division of Surgical Oncology. Dr Pawlik has given our 200 invited talks both nationally and internationally in 20 different countries. Dr. Pawlik has published over 250 articles and 30 book chapters. Dr Pawlik has served on the executive council of several of the premier surgical associations in the United States. Dr Pawlik is a member of a number of professional societies including the Society of Surgical Oncology, the Americas Hepato-Pancreato-Biliary Association, Association for Academic Surgery, Society of Clinical Surgery, as well as the American Surgical Association.


Povoski Photo Oncology CentralStephen P. Povoski

Associate Professor of Surgery, The Ohio State University, OH, USA

Stephen P. Povoski, MD is Associate Professor of Surgery in the Division of Surgical Oncology of the Department of Surgery at The Ohio State University (OSU).

Dr. Povoski’s clinical practice focuses upon breast cancer, including interests in sentinel lymph node technology, image-guided minimally invasive breast biopsy, and the development and refinement of breast cancer imaging, detection, and therapeutics. Dr. Povoski’s specific clinical research interests are broad in their oncologic scope, and are focused upon the development of innovative strategies for perioperative and intraoperative tumor detection and tumor imaging, as well as the development of tumor-directed surgical and non-surgical therapeutic interventions, as related to many different solid malignancies, using various novel molecular targeting agents and various innovative detection probe designs, including technologies that represent both radioactive and non-radioactive detection strategies.

Dr. Povoski has been the principle investigator on multiple OSU institutional clinical trials regarding various methodologies of radioguided imaging and surgery, as specifically related to 18F-FDG-directed imaging and surgery and sentinel lymph node mapping and biopsy technologies. Dr. Povoski has been closely involved in a collaborative effort with Dr. Edward W. Martin, Jr., Professor of Surgery at OSU in the development of new strategies for diagnostic imaging, as well as perioperative/intraoperative tumor detection/imaging using novel anti-TAG-72 monoclonal antibodies and antibody fragments. Their combined efforts have led to the development of a multidisciplinary cancer detection group at OSU.

Dr. Povoski is well-published within several arenas of surgical oncology, including sentinel lymph node mapping and biopsy technologies, minimally-invasive breast biopsy technologies, radioguided surgery, perioperative and intraoperative 18F-FDG-directed imaging and detection technologies, and the applications of anti-TAG-72 monoclonal antibodies, as well as utilization of venous cutdown techniques and venography for chronic indwelling central venous access device placement, utilization of stapling devices for pancreatic surgery, and the evaluation of the utility of preoperative biliary decompression of jaundice caused by pancreatic and peripancreatic malignancies.

Dr. Povoski received his B.S. Degree (summa cum laude) in Biological Sciences from the State University of New York at Buffalo in 1985, his M.D. Degree (summa cum laude) from the State University of New York Health Science Center at Syracuse in 1989, completed his General Surgery Residency training at the University of Cincinnati Medical Center in 1996, and completed his Surgical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in 1998.

Dr. Povoski is on the editorial board of multiple medical journals, and is currently the Deputy Editor of the World Journal of Surgical Oncology and is a Section Editor for BMC Cancer.

Stephen Povoski advises the Oncology Central editorial team on the articles and multimedia content that feature in the following specialties: Breast, Gastrointestinal, Biomarkers & diagnostics, Clinical trials & drug development, Emerging therapies, Imaging, Colorectal.


Ravandi headshotFarhad Ravandi

Professor of Medicine, Department of Leukemia, University of Texas – M. D. Anderson Cancer Center (TX, USA)

Dr Farhad Ravandi graduated from the University of London, England and undertook residency and fellowship training at the Baylor College of Medicine and The University of Texas M.D. Anderson Cancer Center. During this time he specialized in the management of hematological malignancies and stem cell transplantation. He then joined the University of Illinois at Chicago as the director of Leukemia program and the interim director of stem cell transplant program for three years until he joined the Leukemia department of M.D. Anderson in 2003.

Dr Ravandi is board certified in Internal Medicine, Hematology and Medical Oncology. His main areas of interests are therapy of acute myeloid leukemia, as well as rare leukemias including Philadelphia positive acute lymphoblastic leukemia, hairy cell leukemia and T-cell leukemias. He has authored several book chapters and over 300 articles in peer-reviewed journals. He is a member of several professional societies including the American Society of Hematology and American Society of Clinical Oncology.


Sahgal PhotoArjun Sahgal

Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Canada

Arjun Sahgal focuses his research on spinal metastases, brain metastases and primary CNS tumors. He aims to further our understanding of the application of radiotherapy for these diseases, and to develop new therapeutic strategies relating to the application of high precision radiotherapy technology.

His primary research area is in technical evaluation and clinical trials specific to stereotactic body radiotherapy (SBRT) of spinal tumors. In line with high precision treatments, Dr Sahgal participates in the development of non-radiotherapeutic modalities for spine and brain tumors using photodynamic therapy and MRI-guided ultrasound technology, respectively.


Cora Sternberg

Chief of Medical Oncology at the San Camillo and Forlanini Hospitals in Rome, Italy

Dr Cora Sternberg is a graduate of the University of Pennsylvania School Medicine in Philadelphia, PA and is specialized in both Internal Medicine and Medical Oncology. She is currently the Chief of Medical Oncology at the San Camillo and Forlanini Hospitals in Rome, Italy. Dr Sternberg completed her fellowship and was later a staff member at Memorial Sloan-Kettering Cancer Center in New York. She has been elected to the prestigious position of Board Member of the European Organization for the Research and Treatment of Cancer (EORTC). She is Consultant at the Lahey Clinic and holds the position of Adjunct Professor of Medicine in the Department of Medicine, at Tuft’s University School of Medicine, in Boston, Massachusetts. She is a faculty member of the European Society of Medical Oncology (ESMO), of the European School of Oncology (ESO), and of the European School of Urology (ESU) of the European Association of Urology. Dr Sternberg has a great deal of expertise in the treatment of many types of solid tumors and has achieved international recognition for this experience. Dr Sternberg is on the editorial board and is a reviewer for several international scientific journals, and is an invited speaker at innumerable international meetings. She is a lead investigator on many international research grants, has published more than 150 articles and 50 chapters in peer-reviewed journals and books, and is an advocate of patients’ rights and education.

Prof Sternberg is currently the Solid Tumour editor of Critical Reviews in Oncology and Haematology and the Genitourinary Cancer editor for the European Journal of Cancer.


N TritosNicholas A. Tritos

Assistant Professor of Medicine at Harvard Medical School, Boston (MA, USA)

Dr Tritos serves as an Assistant Professor of Medicine at Harvard Medical School, Boston (MA, USA) and staff neuroendocrinologist at the Neuroendocrine Unit, Massachusetts General Hospital.

Dr Tritos’ research and clinical interests include pituitary tumors and growth hormone in adults. Dr Tritos has authored or co-authored over 70 peer-reviewed publications in endocrinology. He serves as the Associate Editor of Endocrine Practice and a regular reviewer for many journals in the field.

Nicholas Tritos advises the Oncology Central editorial team on the articles and multimedia content that feature in the following fields/specialties: endocrine.


PicJan B. Vermorken

Emeritus Professor of Oncology, Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium

Jan B. Vermorken graduated in 1970 from the University of Amsterdam, the Netherlands and undertook his internal medicine training at the University Hospital, Vrije Universiteit in Amsterdam, becoming a board-certified specialist in internal medicine in 1975. He has since worked in the field of medical oncology, initially at the Department of Internal Medicine, later at the Department of Medical Oncology of the same institute, and was officially registered as a Medical Oncologist in the Netherlands in 1992. He received his PhD in Medical Sciences in 1986 from the Vrije Universiteit in Amsterdam. From May 1997 until October 1, 2009, he was Professor of Oncology at the University of Antwerp (UA), and head of the Department of Medical Oncology at the University Hospital Antwerp (UZA), in Edegem, Belgium. After his retirement he remains connected to both University (emeritus Professor) and University Hospital.

His main fields of interest are gynecologic oncology, and head and neck oncology. In addition, he co-ordinated large trials in breast and colon cancer. His main research areas concern early clinical and pharmacological studies with new drugs, studies on the interaction of chemotherapy and radiation therapy and HPV in various malignancies. He devotes a significant amount of time to teaching, professional training, and continuing medical education.

Professor Vermorken is member of the European Society of Gynecology (ESGO) and was ESGO council member from 1989-2000. He is member of the European Organisation for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group since 1980 and served as chairman of that group from 1983 to 1989. Since 1985 he has been a member of the EORTC Head and Neck Cancer Group, served as chairman of its Subcommittee for Chemotherapy (1985-1991), was secretary of the group from 1995 to 2006 and chaired the group from 2006 to 2009. His function within ESMO for years has been one of an officer, in that he chaired the National Representatives Committee from 1991 to 1996 and the Educational Committee from 1996 to 2002. During that whole period he was member of the ESMO Executive Committee. He is considered to be a prominent member of the ESMO Faculty. He is a member of the International Gynecologic Cancer Society, was member of its Council from 1989 to 1993, and is founding member of the Gynecologic Cancer InterGroup, which he chaired from 1997 to 2002.

Professor Vermorken serves on the editorial board of six international journals, reviewer of 13 cancer journals and author or co-author of more than 500 publications. He is Editor-in-Chief of ONCO since 2007. As of January 1, 2009 he is Editor-in-Chief of Annals of Oncology, the official journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology.


Sam_WisemanSam M. Wiseman

Director of Research for the Department of Surgery St. Paul’s Hospital & Providence Health Care, Vancouver, Canada; Faculty of Medicine, University of British Columbia, Vancouver, Canada

Dr Wiseman’s surgical practice and research is concentrated on the treatment of thyroid tumors and parathyroid disease.

Dr Wiseman graduated from medical school at the University of Manitoba in Winnipeg (Canada) and also completed his residency training in General Surgery at the same institution, obtaining his Fellowship in Surgery from the Royal College of Physicians and Surgeons of Canada in 2000.

Dr Wiseman subsequently moved to Buffalo New York where he spent three years in subspecialty fellowship training at Roswell Park Cancer Institute (RPCI). At RPCI he completed an American Head and Neck Society Advanced Training Council approved Head & Neck Surgery Fellowship, a Society of Surgical Oncology approved Surgical Oncology Fellowship, and an Oncology research fellowship that was focused on studying the molecular biology of cancer. After completing his training Dr Wiseman joined the staff at St. Paul’s Hospital in 2003 and is currently an Associate Professor in the Department of Surgery at the University of British Columbia.

Dr Wiseman also carries out other cancer surgeries (such as sentinel node biopsy and lymph node dissection), and general surgery operations (such as laparoscopic cholecystectomy and hernia repair). Dr Wiseman has also continued to study other human cancer types including; breast, colon, rectal, and lung cancers. His research has taken a translational approach, or applied new knowledge/discoveries learned in the laboratory to address important clinical diagnostic, prognostic and treatment questions. Dr Wiseman has many research collaborators (both clinicians and scientists) and is involved in the training and supervision of many undergraduate, graduate, and postgraduate students.

In 2005 Dr Wiseman was the first surgeon in the history of British Columbia to receive the prestigious Michael Smith Foundation for Health Research Scholar Award. In 2007 Dr Wiseman was selected from surgeons world-wide to receive the prestigious American College of Surgeons Travelling Fellowship to Japan. Dr Wiseman was a recipient of Canada’s Top 40 Under 40 Award in 2008. Dr Wiseman and his peers were selected from over 1100 nominees by an independent Advisory Board based on on five key criteria: vision and leadership; innovation and achievement; impact; community involvement and contribution; and strategy for growth.

Dr Wiseman has served as a reviewer and editor for many medical journals, acting as a grant reviewer for several granting agencies, member of the Executive Council of the British Columbia Cancer Agency Surgical Oncology Network, Department of Surgery representative for the University of British Columbia Clinical Investigator Program, Endocrine Tumor Group Chair for the British Columbia Cancer Agency, and he is the Director of Research for the Department of Surgery St. Paul’s Hospital & Providence Health Care.


Sue Yom headshotSue S. Yom

Associate Professor of Clinical Radiation Oncology and Director of Head and Neck and Thoracic Radiotherapy, Department of Radiation Oncology & Department of Otolaryngology – Head and Neck Surgery, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco School of Medicine (CA, USA)

Dr Sue S. Yom is Associate Professor of Clinical Radiation Oncology and Director of Head and Neck and Thoracic Radiotherapy, appointed in the Department of Radiation Oncology and the Department of Otolaryngology – Head and Neck Surgery, within the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco School of Medicine (CA, USA).

Dr Yom earned her undergraduate degree from Rice University (TX, USA) and completed her medical degree at the University of Pennsylvania School of Medicine (PA, USA). Dr Yom completed her internship and residency training at the University of Texas M. D. Anderson Cancer Center in Houston (TX, USA).

She is member of numerous reviewer and editor panels for scientific cancer publications and has been listed as one of the Best Doctors in America every year since 2009. She is a Senior Editor at the International Journal of Radiation Oncology, Biology, Physics and serves on the Editorial Board for Journal of Radiation Oncology and Lung Cancer.

Dr Yom is currently a member of the Executive Committee of the American Radium Society and serves as Chair of the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology – Head and Neck. She is also a member of the National Comprehensive Cancer Network Head and Neck Cancers Panel and the Head and Neck Committee of the NRG Oncology Group.


ZalaudekIris Zalaudek

Associate Professor at the Division of Dermatology, Medical University of Graz, Austria

Prof. Iris Zalaudek is Board certified Dermatologist and since 2008 Associate Professor at the Division of Dermatology of the Medical University of Graz; Austria. She is Director of the Master of Science in Dermoscopy and Preventive Dermato-Oncology at the Department of Dermatology of the Medical University of Graz; Austria Her main research fields are skin imaging techniques such as total body mapping, dermoscopy, digital dermoscopic monitoring, in vivo and ex vivo reflectance confocal microscopy and clinical dermato-oncology including topical and systemic treatment of skin tumors.

She has published more than 270 scientific articles in international peer-review journals. Her combined publications have received an impact factor of 796 and a h-index value of 22 (February 2013). She has conducted and participated in several clinical trials and research projects.

She frequently lectures on these topics nationally and internationally. In 2003 her work was awarded by the Hans-Weitgasser Price from the Styrian Association of Dermatologists. In 2008, she was awarded the Best Researcher of the Medical University of Graz, Austria.

Prof. Iris Zalaudek was invited as Research Fellow to the Dermatology Department of Second University of Naples, Italy (2004 to 2006) and worked as consultant at the Melanoma Unit of the Dermato-Oncology Department of the San Gallicano Institute in Rome, Italy (2009 to 2011). Since 2011, she is working as consultant at the Dermatology and Skin Cancer Unit of the Arcispedale Santa Maria Nuova – IRCCS in Reggio Emilia, Italy.

At current, she is member of the management committee and work group leader of the EU_COST Action BM1205 with the title European Network for Skin Cancer Detection using Laser Imaging.

Prof. Zalaudek is Secretary elect of the International Dermoscopy Society (www.dermoscopy-ids.org), Board Member of the European Academy of Dermato Oncology (www.eado.org) and Director of the Master of Science in Dermoscopy and Dermato-Oncology of the Medical University of Graz, Austria (www.medunigraz.at/dermoscopy).

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.